Midatech Platforms Will Drive Specialty Pharma Share Of Voice
Specialty pharma has been one of the hottest growth areas in recent years but with many companies entering into the space it is now a crowded marketplace. Speaking at Biotech Showcase 2018, Midatech Pharma CEO Jim Phillips told Scrip how the company’s three proprietary drug delivery platforms will underpin its ambitions to gain share of voice in the US and beyond, while outlining the prospects for its current pipeline.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.